ClinicalTrials.gov record
Active, not recruiting Early Phase 1 Interventional Results available

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

ClinicalTrials.gov ID: NCT03215095

Public ClinicalTrials.gov record NCT03215095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers

Study identification

NCT ID
NCT03215095
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
11 participants

Conditions and interventions

Conditions

Interventions

  • Durvalumab (Medi4736) Drug
  • Radioiodine (RAI) Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 9, 2017
Primary completion
Feb 5, 2023
Completion
Jun 30, 2026
Last update posted
Jul 16, 2025

2017 – 2026

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Bergen Montvale New Jersey 07645
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Nassau Uniondale New York 11553

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03215095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03215095 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →